Innovative Technology RevealDx offers AI-enabled radiomics software for lung cancer diagnostics, positioning it as a cutting-edge solution in medical imaging that can be expanded through partnerships and integration with healthcare providers seeking advanced diagnostic tools.

Strategic Partnerships The company's collaborations with organizations like TriHealth, Sirona Medical, and Volpara Health highlight opportunities to approach similar healthcare networks and diagnostic centers interested in enhancing lung cancer detection accuracy.

Regulatory Advancements Recent MDR certification of RevealAI-Lung and ongoing medical device licensing efforts demonstrate a pathway to expand market reach, appealing to hospitals and clinics prioritizing compliant and validated lung cancer diagnostic solutions.

Funding & Growth With over four million dollars in funding and a revenue range of up to ten million dollars, RevealDx is positioned for scaling its software solutions, making it a compelling target for investors and enterprise clients aiming for innovative healthcare analytics.

Market Positioning Recognition as an award finalist at the 2026 GeekWire Awards and active participation in industry events enhance the company's visibility, creating networking opportunities with health tech stakeholders and potential customers across the Pacific Northwest and beyond.